Parents have been waiting a long time for an effective weapon to prevent bronchiolitis. From Friday September 15, they will be able to vaccinate their baby against the respiratory syncytial virus (RSV), which is responsible for the illness that led to 35,000 babies being hospitalized last year, including 2,500 in intensive care. A revolution made possible by the monoclonal antibody nirsevimab, marketed as Beyfortus by Sanofi and AstraZeneca Laboratories.
After receiving marketing authorization in Europe, this new treatment was approved by the highest health authority on 1eh August It is recommended for all babies born after the end of the last epidemic season, i.e. on February 6, 2023. “This is the first time that protection against bronchiolitis can be offered to an entire generation of children.”rejoices T.r: Loïc de Pontual, a pediatrician at the Jean-Verdie Hospital in Bondi. Older children, but with special risks…
Source: Le Figaro
I am John Sinkler, a professional writer and journalist for Buna Times. I specialize in writing about entertainment-related topics and have been doing so for several years now. My work has been featured on multiple platforms and I’m proud to say that it’s gained recognition from many people in the industry. Aside from working at Buna Times, I also write freelance articles for other publications.